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a  b  s  t  r  a  c  t
Brivaracetam  (BRV),  a  selective,  high-afﬁnity  ligand  for synaptic  vesicle  protein  2A, is  a new  antiepileptic
drug  (AED)  for  adjunctive  treatment  of  focal  (partial-onset)  seizures  in  adults  with  epilepsy.  This  post-
hoc  analysis  was  conducted  to  explore  the  efﬁcacy  of  adjunctive  BRV  in  patients  with  prior  levetiracetam
(LEV)  exposure  and  whether  changes  in  efﬁcacy  were related  to  the  similar  mechanism  of  action  of  these
two  drugs.  Data  were  pooled  from  three  Phase  III studies  (NCT00490035;  NCT00464269;  NCT01261325)
of  adults  with  focal  seizures  taking  1–2  AEDs  who  received  placebo  or BRV  50–200  mg/day  without  titra-
tion  over  a 12-week  treatment  period.  Patients  taking  concomitant  LEV  at enrollment  were  excluded  from
this analysis.  Patients  were  categorized  by their  status  of  prior  exposure  to LEV,  carbamazepine  (CBZ),
topiramate  (TPM),  or lamotrigine  (LTG),  to investigate  any  consistent  trend  towards  reduced  response
in  AED-exposed  subgroups  compared  to AED-naïve  subgroups,  regardless  of the  mechanism  of action.
Study  completion  rates,  percent  reduction  from  baseline  in focal  seizure  frequency  over  placebo,  ≥50%
responder  rates,  and  tolerability  were  evaluated  for each  subgroup.  A total  of  1160  patients  were  inves-
tigated.  Study  completion  rates  were  similar  in  the  AED-exposed  subgroups  and AED-naïve  subgroups.
In  subgroups  with  (531 patients)  or without  (629 patients)  prior LEV  exposure,  ≥50%  responder  rates  for
each  dose  of BRV  compared  with  placebo  were  generally  higher  among  the  LEV-naïve  subgroups  than
the  previously  LEV-exposed  subgroups.  LEV-exposed  subgroups  receiving  BRV  doses  ≥50 mg/day  showed
greater  ≥50%  responder  rates  than  those  receiving  placebo.  Similar  results  were  observed  for  CBZ,  TPM,
and  LTG.  Previous  treatment  failure  with  commonly  prescribed  AEDs  (LEV,  CBZ,  TPM,  or LTG)  is associated
with  a  reduced  response  to BRV  irrespective  of  the  mechanism  of  action.  Hence,  this  post-hoc  analysis
indicates  that  previous  treatment  failure  with  LEV does  not preclude  the use  of BRV  in patients  with
epilepsy.
©  2017  UCB  Pharma.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Brivaracetam (BRV) is a new antiepileptic drug (AED) derived
from a targeted drug discovery program (Klitgaard et al., 2016).
BRV is a selective, high-afﬁnity ligand for synaptic vesicle pro-
tein 2A (SV2A) (Gillard et al., 2011). Its binding afﬁnity with SV2A
∗ Corresponding author at: Department of Neurology, Thomas Jefferson Univer-
sity, 901 Walnut Street, Suite 435, Philadelphia, PA 19107, USA.
E-mail address: aliasadipooya@yahoo.com (A.A. Asadi-Pooya).
1 Employee of UCB Pharma at the time when the studies and analysis were con-
ducted.
is higher than that of levetiracetam (LEV), another SV2A ligand
(Gillard et al., 2011). The tolerability and efﬁcacy of adjunctive BRV
in patients with drug-resistant focal (partial-onset) seizures with
or without secondary generalization have been investigated and
demonstrated in three pivotal Phase III studies (Biton et al., 2014;
Klein et al., 2015a; Rheims and Ryvlin, 2014). One  recent meta-
analysis (Ma  et al., 2015) identiﬁed ﬁve randomized, controlled
trials of BRV in the treatment of drug-resistant focal epilepsies and
included a total of 1639 patients. This meta-analysis demonstrated
a statistically signiﬁcant improvement in seizure control compared
with placebo, and favorable tolerability of therapeutic doses of
BRV (50–200 mg/day) as an adjunctive treatment for drug-resistant
focal epilepsy.
http://dx.doi.org/10.1016/j.eplepsyres.2017.02.007
0920-1211/© 2017 UCB Pharma. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
0/).
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Approximately one-third of individuals with epilepsy have inad-
equate seizure control despite the use of appropriate AEDs (Kwan
and Brodie, 2000b). In addition, treatment in patients with epilepsy
is often complicated by the unpredictability of the efﬁcacy of any
given AED. This uncertainty of response, particularly in patients
with drug-resistant seizures, may  obfuscate the use of any newly
developed AED (Kwan et al., 2010). This is particularly important
if the newly developed AED has similarities to an already exist-
ing AED. For example, it is helpful to know whether failure of a
currently available AED, such as LEV, precludes the prescription
of a newly developed AED (i.e. BRV) that also targets one of the
same molecular sites of action. It is noteworthy that BRV differs
signiﬁcantly from LEV by its selective, high afﬁnity, and differential
interaction with SV2A, as well as a higher lipophilicity, correlating
with a more rapid brain penetration in preclinical studies (Klitgaard
et al., 2016). BRV also differs from LEV by neither inhibiting the
-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptor (Margineanu and Klitgaard, 2002; Rigo et al., 2004) nor
the high voltage-activated calcium channels at therapeutically rel-
evant concentrations (Klitgaard et al., 2016; Niespodziany et al.,
2015; Pisani et al., 2004). In a post-hoc analysis of study N01358,
efﬁcacy with adjunctive BRV was demonstrated in subgroups with
prior LEV exposure and also in LEV-naïve patients, but the response
appeared to be greater in the LEV-naïve population (Klein et al.,
2015a). The aim of the current post-hoc analysis was to explore
the efﬁcacy of adjunctive BRV in patients with or without prior LEV
exposure in a larger patient population pooled from three Phase
III studies, and to determine whether any observed trend towards
reduced efﬁcacy in LEV-exposed patients compared with LEV-naïve
patients was related to mechanism of action. Some other com-
monly prescribed AEDs [carbamazepine (CBZ), lamotrigine (LTG),
and topiramate (TPM)] were also investigated to see whether prior
exposure to these drugs was related to BRV efﬁcacy. Tolerability
data were evaluated for each subgroup. These data may  be helpful
in the decision-making process when considering the use of BRV
for patients who have previously failed other AEDs.
2. Methods
This is a post-hoc analysis of data pooled from three Phase III
studies (N01252, NCT00490035; N01253, NCT00464269; N01358,
NCT01261325) (Biton et al., 2014; Klein et al., 2015a; Rheims and
Ryvlin, 2014). All patients included in this analysis were random-
ized to BRV 50, 100, and 200 mg  per day or placebo. Patients who
were on concomitant LEV at the time of enrollment were excluded
from this analysis. Patients were categorized by their status of prior
exposure to LEV, CBZ, TPM, or LTG. We  deﬁned AED-naïve as “never
having been exposed to that particular AED” and AED-exposed as
“having been exposed to that particular AED” (during the past 5
years for studies N01252 and N01253, and during the patient’s
lifetime before study entry for study N01358). For AED-exposed
patients, that speciﬁc AED had to have been discontinued at least
90 days prior to enrollment in the Phase III study. Demographic and
baseline epilepsy characteristics, and the number (%) of patients
who completed the study, were summarized for each subgroup.
The efﬁcacy population comprised all randomized patients who
received at least one dose of study drug and had at least one post-
baseline seizure diary entry. Percent reduction from baseline in
focal seizure frequency over placebo, and ≥50% responder rates,
were evaluated for each subgroup of patients. A further subgroup
analysis was  conducted for ≥50% responder rate based on the num-
ber of prior AEDs (≤2, 3–5, and ≥6). This subgroup analysis was
conducted on a modiﬁed efﬁcacy population that included patients
taking concomitant LEV. In this analysis, a prior AED was deﬁned as
any AED that was  taken previously and/or concomitantly at study
entry.
Treatment group comparisons (BRV ≥50 mg/day vs. placebo) for
≥50% responder rates were based on a logistic regression model
with ≥50% responder rate as the outcome, and with effects for treat-
ment, study, and log-transformed baseline focal seizure frequency
as a continuous covariate. The logistic regression model was used
to examine the relationship between the ≥50% responder rate and
a set of predictor variables. The model used a logit transformation
of the outcome, which is the log of the odds or the ratio of the prob-
ability of the outcome (yes for ≥50% response) to the probability
of no outcome (no for ≥50% response). All statistical analyses were
exploratory.
Details of the study population, efﬁcacy assessments, safety and
tolerability assessments, and ethical issues are explained in the pre-
vious Phase III studies (Biton et al., 2014; Klein et al., 2015a; Rheims
and Ryvlin, 2014).
3. Results
A total of 1160 patients were included in this analysis. Over-
all, 531 patients had previously been exposed to LEV and 629
were LEV-naïve. Demographic and baseline epilepsy characteris-
tics are shown in Table 1. Demographic characteristics were similar
between the AED-exposed and AED-naïve subgroups. However, the
proportion of patients who  had previously failed at least 5 AEDs
was higher among previously LEV-, CBZ-, TPM-, and LTG-exposed
subgroups (61–69%) than among subgroups who  had never taken
those particular AEDs (13–17%).
Table 1
Demographic and baseline epilepsy characteristics, by prior exposure to levetiracetam, carbamazepine, topiramate, or lamotrigine (efﬁcacy population).
Levetiracetam Carbamazepine Topiramate Lamotrigine
Exposed
(n = 578)
Naïve
(n = 743)
Exposed
(n = 424)
Naïve
(n = 339)
Exposed
(n = 428)
Naïve
(n = 696)
Exposed
(n = 349)
Naïve
(n = 639)
Age, mean (SD), years 39.8 (13.3) 36.9 (12.6) 39.6 (13.5) 37.4 (14.2) 38.5 (12.8) 38.3 (13.4) 39.7 (13.2) 38.0 (13.1)
Female, n (%) 318 (55.0) 341 (45.9) 229 (54.0) 165 (48.7) 232 (54.2) 306 (44.0) 188 (53.9) 282 (44.1)
No.  of prior AEDs, n (%)
0–1 29 (5.0) 304 (40.9) 24 (5.7) 136 (40.1) 11 (2.6) 280 (40.2) 5 (1.4) 263 (41.2)
2–4  176 (30.4) 343 (46.2) 140 (33.0) 145 (42.8) 123 (28.7) 310 (44.5) 107 (30.7) 280 (43.8)
≥5  373 (64.5) 96 (12.9) 260 (61.3) 58 (17.1) 294 (68.7) 106 (15.2) 237 (67.9) 96 (15.0)
Baseline focal seizure
frequency/28 days, median (Q1, Q3)
11.0 (6.4, 26.8) 7.9a (5.0, 15.9) 9.6 (5.8, 24.2) 8.3 (5.5, 19.2) 9.7 (5.8, 24.5) 8.5b (5.3, 18.8) 11.3 (6.1, 25.8) 8.0c (5.1, 16.9)
The efﬁcacy population comprised randomized patients who  received at least one dose of study drug and had at least one post-baseline seizure diary entry; patients taking
concomitant LEV were excluded.
an = 742, bn = 695, cn = 638; patients without baseline seizure frequency were excluded.
AED, antiepileptic drug; Q1, ﬁrst quartile; Q3, third quartile; SD, standard deviation.
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Fig. 1. ≥50% responder rates in patients treated with brivaracetam, with or without prior levetiracetam (A), carbamazepine (B), topiramate (C) or lamotrigine (D) exposure
(efﬁcacy population).
p-values (BRV vs. placebo) are derived from a logistic regression model with effects for treatment, study, and log-transformed baseline focal seizure frequency as a continuous
covariate. All p-values are exploratory. The efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline
seizure diary entry; patients taking concomitant LEV were excluded.
BRV, brivaracetam; CBZ, carbamazepine; LEV, levetiracetam; LTG, lamotrigine; TPM, topiramate.
Numbers of patients enrolled, study completion (retention)
rates, and percent reduction from baseline in focal seizure fre-
quency over placebo for each subgroup of patients are shown in
Tables 2–5, and ≥50% responder rates for each subgroup of patients
are shown in Fig. 1.
Retention rates, which are predominantly a reﬂection of tolera-
bility, were similar in the AED-exposed and AED-naïve subgroups.
The 12-week retention rates during the study period were >84% in
all subgroups (all doses and all drugs) (Tables 2–5).
Percent reduction from baseline in focal seizure frequency over
placebo was numerically greater in BRV-treated, LEV-naïve sub-
groups than in BRV-treated, LEV-exposed subgroups (Table 2). A
similar pattern was seen for subgroups with and without prior
exposure to CBZ, TPM, and LTG (Tables 3–5 ).
The ≥50% responder rates for BRV compared with placebo were
higher among the LEV-naïve subgroups than the LEV-exposed sub-
groups (Fig. 1A). However, LEV-exposed subgroups receiving BRV
doses ≥50 mg/day showed higher ≥50% responder rates than cor-
responding placebo subgroups. Similar results were observed in
subgroups with or without prior CBZ, TPM, and LTG exposure,
although the differences between the corresponding AED-exposed
and AED-naïve subgroups for BRV versus placebo were less marked
for CBZ and LTG (Fig. 1B–D).
Responder rates for subgroups of patients with ≤2, 3−5, and
≥6 prior AED exposures are shown in Table 6. When the number
of prior AEDs was 3–5, the LEV-naïve subgroup showed a greater
response with BRV, compared with placebo, than the LEV-exposed
subgroup. A similar trend was  observed with other AEDs (i.e. CBZ,
TPM, and LTG). In subgroups with ≤2 prior AEDs, the number of
patients was too small for statistical analysis. No clear pattern was
seen in subgroups with ≥6 prior AED exposures.
4. Discussion
BRV is a new AED that has demonstrated efﬁcacy as an adjunc-
tive treatment for adults with focal epilepsies and has been shown
to be well tolerated (Biton et al., 2014; Klein et al., 2015a; Kwan
et al., 2014; Rheims and Ryvlin, 2014). A previous post-hoc analy-
sis indicated that adjunctive BRV was effective both in subgroups
of patients with prior exposure to LEV and in those who were
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Table  2
Numbers of patients enrolled, study completion rates (over 12 weeks), and percent reduction from baseline in focal seizure frequency over placebo in patients treated with
brivaracetam (BRV), with or without prior levetiracetam (LEV) exposure (efﬁcacy population).
Placebo BRV 50 mg/day BRV 100 mg/day BRV 200 mg/day BRV ≥50 mg/day
LEV- exposed Number of patients 191 48 158 134 340
Number of patients who completed the study (%) 184 (96.3) 43 (89.6) 141 (89.2) 119 (88.8) 303 (89.1)
Percent reduction from baseline in focal seizure
frequency over placebo
– 5.1 17.3 20.3 12.8
LEV-  naïve Number of patients 227 113 174 115 402
Number of patients who completed the study (%) 212 (93.4) 104 (92.0) 158 (90.8) 106 (92.2) 368 (91.5)
Percent reduction from baseline in focal seizure
frequency over placebo
– 26.1 30.0 27.3 28.7
The efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline seizure diary entry; patients taking
concomitant LEV were excluded.
Table 3
Numbers of patients enrolled, study completion rates (over 12 weeks), and percent reduction from baseline in focal seizure frequency over placebo in patients treated with
brivaracetam (BRV), with or without prior carbamazepine (CBZ) exposure (efﬁcacy population).
Placebo BRV 50 mg/day BRV 100 mg/day BRV 200 mg/day BRV ≥50 mg/day
CBZ- exposed Number of patients 143 34 113 98 245
Number of patients who completed the study (%) 137 (95.8) 31 (91.2) 100 (88.5) 88 (89.8) 219 (89.4)
Percent reduction from baseline in focal seizure
frequency over placebo
– 5.4 23.1 19.2 15.0
CBZ-  naïve Number of patients 103 46 89 58 193
Number of patients who completed the study (%) 96 (93.2) 39 (84.8) 81 (91.0) 51 (87.9) 171 (88.6)
Percent reduction from baseline in focal seizure
frequency over placebo
– 23.3 30.3 17.7 26.4
The efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline seizure diary entry; patients taking
concomitant LEV were excluded.
Table 4
Numbers of patients enrolled, study completion rates (over 12 weeks), and percent reduction from baseline in focal seizure frequency over placebo in patients treated with
brivaracetam (BRV), with or without prior topiramate (TPM) exposure (efﬁcacy population).
Placebo BRV 50 mg/day BRV 100 mg/day BRV 200 mg/day BRV ≥50 mg/day
TPM- exposed Number of patients 123 38 115 104 257
Number of patients who completed the study (%) 120 (97.6) 35 (92.1) 99 (86.1) 90 (86.5) 224 (87.2)
Percent reduction from baseline in focal seizure
frequency over placebo
– 13.1 17.9 18.2 13.1
TPM-  naïve Number of patients 212 113 170 117 400
Number of patients who completed the study (%) 197 (92.9) 104 (92.0) 158 (92.9) 108 (92.3) 370 (92.5)
Percent reduction from baseline in focal seizure
frequency over placebo
– 24.4 29.6 31.3 28.6
The efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline seizure diary entry; patients taking
concomitant LEV were excluded.
Table 5
Numbers of patients enrolled, study completion rates (over 12 weeks), and percent reduction from baseline in focal seizure frequency over placebo in patients treated with
brivaracetam (BRV), with or without prior lamotrigine (LTG) exposure (efﬁcacy population).
Placebo BRV 50 mg/day BRV 100 mg/day BRV 200 mg/day BRV ≥50 mg/day
LTG- exposed Number of patients 105 27 97 82 206
Number of patients who completed the study (%) 102 (97.1) 24 (88.9) 83 (85.6) 74 (90.2) 181 (87.9)
Percent reduction from baseline in focal seizure
frequency over placebo
– 1.8 22.5 24.0 13.1
LTG-  naïve Number of patients 202 96 149 106 351
Number of patients who completed the study (%) 190 (94.1) 90 (93.8) 139 (93.3) 96 (90.6) 325 (92.6)
Percent reduction from baseline in focal seizure
frequency over placebo
– 28.0 30.6 28.5 29.1
The efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline seizure diary entry; patients taking
concomitant LEV were excluded.
LEV-naïve, although the effect appeared to be greater in the LEV-
naïve population (Klein et al., 2015a). In the current post-hoc
analysis, we investigated whether prior exposure to – and failure
of – speciﬁc, commonly used AEDs (i.e. LEV, CBZ, TPM, or LTG) is a
marker for lack of response to BRV in patients with drug-resistant
focal epilepsy, a hypothesis that was not conﬁrmed by the results.
AED treatment in patients with epilepsy is often complicated by
many factors, including the unpredictability of efﬁcacy (Kwan et al.,
2010). It has been observed that, if the ﬁrst appropriately chosen
AED is not efﬁcacious in controlling seizures, the outcome with
respect to seizure control is less favorable with the next prescribed
AED (Kwan and Brodie, 2000a). In a cohort of 478 patients who
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Table 6
≥50% responder rates, by prior AED exposure and number of prior AEDs (modiﬁed efﬁcacy population).
Number of prior AEDs
≤2 3–5 ≥6
Placebo BRV ≥50 mg/day Placebo BRV ≥50 mg/day Placebo BRV ≥50 mg/day
LEV-exposed Number of patients 15 14 61 105 115 221
≥50%  responder rate, n (%) 3 (20.0) 7 (50.0)
p  = 0.128
15 (24.6) 37 (35.2)
p = 0.224
16 (13.9) 58 (26.2)
p = 0.010
LEV-naïve Number of patients 94 180 106 178 27 44
≥50%  responder rate, n (%) 23 (24.5) 84 (46.7)
p < 0.001
23 (21.7) 75 (42.1)
p < 0.001
5 (18.5) 19 (43.2)
p = 0.088
CBZ-exposed Number of patients 12 20 56 94 82 153
≥50%  responder rate, n (%) 4 (33.3) 13 (65.0)
p = 0.034
16 (28.6) 39 (41.5)
p = 0.099
10 (12.2) 46 (30.1)
p = 0.007
CBZ-naïve Number of patients 54 89 52 90 18 40
≥50%  responder rate, n (%) 14 (25.9) 41 (46.1)
p = 0.030
8 (15.4) 32 (35.6)
p = 0.011
3 (16.7) 11 (27.5)
p = 0.291
TPM-exposed Number of patients 5 11 44 82 82 182
≥50%  responder rate, n (%) 4 (80.0) 4 (36.4)
p  = 0.150
13 (29.5) 31 (37.8)
p = 0.652
12 (14.6) 51 (28.0)
p = 0.025
TPM-naïve Number of patients 92 180 108 197 40 62
≥50%  responder rate, n (%) 19 (20.7) 79 (43.9)
p < 0.001
23 (21.3) 74 (37.6)
p = 0.003
6 (15.0) 18 (29.0)
p = 0.058
LTG-exposed Number of patients 10 12 33 53 71 157
≥50%  responder rate, n (%) 0 (0) 6 (50.0) 5 (15.2) 20 (37.7)
p = 0.054
13 (18.3) 46 (29.3)
p = 0.109
LTG-naïve Number of patients 84 160 109 162 29 56
≥50%  responder rate, n (%) 20 (23.8) 73 (45.6)
p = 0.001
22 (20.2) 61 (37.7)
p = 0.003
3 (10.3) 17 (30.4)
p = 0.045
All p-values are exploratory. The modiﬁed efﬁcacy population comprised randomized patients who received at least one dose of study drug and had at least one post-baseline
seizure  diary entry; patients taking concomitant LEV were included.
AED, antiepileptic drug; BRV, brivaracetam; CBZ, carbamazepine; LEV, levetiracetam; LTG, lamotrigine; TPM, topiramate.
received newly administered AED treatments in a single epilepsy
clinic (Schiller and Najjar, 2008), the response to newly adminis-
tered AEDs was highly dependent on the past treatment history.
Seizure freedom rates decreased from 61.8% for the ﬁrst AED to
41.7%, 16.6%, and 0% after 1, 2–5, and 6–7 prior AED failures, respec-
tively. In the current study, we observed that BRV, compared with
placebo, is more efﬁcacious in AED-naïve subgroups than in those
who have previously been exposed to any of the particular AEDs
tested (i.e. LEV, CBZ, TPM, and LTG). In other words, exposure
to prior AEDs can predict a reduced response to BRV. It is likely
that mechanism of action does not play a major role in this phe-
nomenon, as we observed similar trends with prior exposure to
AEDs with different mechanisms of action. We  also did not see a
consistent pattern of response in subgroups of patients who had
previously been exposed to ≥6 AEDs. Because patients with ≥6
prior AED failures are highly unlikely to respond to the next AED,
this may  be a sufﬁcient reason to exclude this subgroup from the
design of future AED trials.
There are various factors that may  contribute to the reduced efﬁ-
cacy observed in different patient populations. Genetic variations
may explain some of the inter-individual variability in response to
AEDs among patients (Franco and Perucca, 2015; Shaheen et al.,
2014). The number of previously tried and failed AEDs, which is
indicative of drug resistance and severity of epilepsy, may  also
explain reduced drug responses observed among patients with
refractory epilepsy (Klein et al., 2015b; Schiller and Najjar, 2008;
Voll et al., 2015). Another plausible mechanism of drug resistance
is the overexpression of multidrug efﬂux transporters, such as
P-glycoprotein (P-gp), which would result in lower interstitial lev-
els of AEDs surrounding the epileptogenic tissue (Loscher, 2005;
Schmidt and Loscher, 2005; Sisodiya et al., 2002). Animal and
human studies support the multidrug transporter hypothesis of
multidrug-resistant epilepsy (Asadi-Pooya et al., 2013; Lazarowski
and Czornyj, 2011).
Despite the observed reduced efﬁcacy of BRV in AED-exposed
subgroups compared to AED-naïve subgroups, BRV was more
efﬁcacious when compared with placebo in the AED-exposed sub-
groups. This observation was  consistent for all the investigated
prior AEDs. Therefore, BRV was efﬁcacious for the treatment of focal
epilepsies even in patients who had been previously exposed to
and failed other commonly prescribed AEDs. This is an important
ﬁnding and offers promise for patients with multidrug-resistant
epileptic seizures.
With respect to BRV tolerability, we observed that retention
rates were reasonably high (84.8–93.8%) in all dose groups. In sev-
eral previous studies, including the original studies for the current
analysis, BRV has demonstrated a good safety and tolerability pro-
ﬁle (Biton et al., 2014; Klein et al., 2015a; Rheims and Ryvlin, 2014).
In a small, open-label, prospective, exploratory study of 29 patients
with epilepsy switching from LEV to BRV (Yates et al., 2015), non-
psychotic behavioral adverse events were evaluated. At the end
of the treatment period, 93.1% of patients that switched to BRV
had clinically meaningful reductions in behavioral adverse events.
Mean change from baseline to Week 12 in Patient-Weighted Qual-
ity of Life in Epilepsy Inventory-Form-31 (QOLIE-31-P) total score
was 12.1, indicating improved health-related quality of life. These
data suggest that BRV may  have a better proﬁle with respect to
behavioral adverse events compared with LEV (Yates et al., 2015).
As this was  a post-hoc study, the results of our analysis should
be viewed as exploratory and require conﬁrmation by prospective
studies. Furthermore, all p-values in this study should be consid-
ered in the context of an exploratory analysis. In addition, the
numbers of patients in some of the subgroups were too small for
valid statistical analysis.
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In conclusion, while prior exposure to commonly prescribed
AEDs (LEV, CBZ, TPM, and LTG) is associated with a reduced
response to BRV, this effect is seen irrespective of the mechanism
of action. This is consistent with the previous studies cited above,
showing that the likelihood of response to any AED decreases as
the number of prior AEDs increases. This post-hoc analysis there-
fore indicates that previous treatment failure with LEV does not
preclude the use of BRV.
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